Associate Professor Noriyuki Kurita and his team at Toyohashi University of Technology have identified two promising tuberculosis drug candidates using advanced molecular simulation — a breakthrough that sidesteps one of medicine's trickiest problems: when tuberculosis treatments inadvertently sabotage each other.
Here's the puzzle they solved: rifampicin, a standard tuberculosis drug, triggers the body to produce more cytochrome P450 (CYP), an enzyme that breaks down medications. This accelerates the degradation of other drugs taken alongside it, rendering them less effective. For tuberculosis patients juggling multiple medications, this interaction can be the difference between recovery and treatment failure. Until now, developing compounds that could safely inhibit this enzyme without harming the patient has proven extraordinarily difficult.
The Japanese-Thai research team, led in Thailand by Associate Professor Pornpan Pungpo from Ubon Ratchathani University, took a different approach. Rather than targeting the tuberculosis bacterium itself—which risks breeding resistant strains—they designed inhibitors to block the CYP enzyme that the bacterium relies on. This strategy reduces the likelihood of bacterial mutation and resistance, potentially offering sustained therapeutic efficacy over years rather than months.
The real innovation lies in how they found these compounds. Conventional molecular simulations have historically struggled to accurately model how inhibitors bind to CYP's active site, particularly around the heme iron at its center. The coordination bond between heme iron and inhibitors is crucial for effective inhibition, but traditional calculation methods couldn't reliably reproduce this binding state. Kurita's team developed a novel molecular force field that accurately accounts for coordination bonding and charge transfer around the heme iron—a technical achievement that transforms what was previously a black box into a precision tool.
With this new simulation framework in place, the researchers used the fragment molecular orbital (FMO) method to analyze electronic-structure binding characteristics, identifying which amino acid residues were critical for inhibitor attachment. Working collaboratively across the Japan-Thailand partnership, they systematically introduced various substituents into candidate compounds and screened them using supercomputing resources. Out of eleven candidates selected for their favorable drug properties and low toxicity, two emerged as standouts—both demonstrating stronger binding affinity to CYP than existing inhibitors.
The research, published in the Journal of Molecular Graphics and Modelling and In Silico Research in Biomedicine, represents more than just technical success. Master's students Nagura and Chimura, the papers' lead authors, spent two months at the collaborative laboratory in Thailand, where direct engagement with local researchers proved invaluable. As they reflected, the breakthrough depended not only on solving a computational challenge but on building the kind of research partnership where ideas could flow freely across borders. Their willingness to sit down with colleagues and work through binding properties together—rather than relying solely on algorithms—accelerated the discovery process in ways that isolation could never have achieved.
The implications extend beyond tuberculosis treatment. Kurita's team plans to apply this molecular simulation method to additional enzyme proteins, potentially unlocking new therapeutic strategies for other diseases where drug-drug interactions remain a clinical headache. For patients with tuberculosis, particularly those in regions where the disease burden remains highest, these two candidates represent hope that the next generation of treatment combinations might finally work in harmony rather than against each other.